Premium
Consensus guidelines for diagnosis, prophylaxis and management of P neumocystis jirovecii pneumonia in patients with haematological and solid malignancies, 2014
Author(s) -
Cooley L.,
Dendle C.,
Wolf J.,
Teh B. W.,
Chen S. C.,
Boutlis C.,
Thursky K. A.
Publication year - 2014
Publication title -
internal medicine journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.596
H-Index - 70
eISSN - 1445-5994
pISSN - 1444-0903
DOI - 10.1111/imj.12599
Subject(s) - medicine , immunosuppression , concomitant , pneumocystis jirovecii , malignancy , pneumonia , trimethoprim , intensive care medicine , pneumocystis carinii , antibiotics , microbiology and biotechnology , biology
P neumocystis jirovecii infection ( PJP ) is a common cause of pneumonia in patients with cancer‐related immunosuppression. There are well‐defined patients who are at risk of PJP due to the status of their underlying malignancy, treatment‐related immunosuppression and/or concomitant use of corticosteroids. Prophylaxis is highly effective and should be given to all patients at moderate to high risk of PJP . Trimethoprim‐sulfamethoxazole is the drug of choice for prophylaxis and treatment, although several alternative agents are available.